Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

Decided June 4, 2026. Ketanji Brown Jackson delivered the opinion of the Court.

Docket 24-889 · 608 U.S. ___ (2026)

Amarin has failed to state a claim for actively inducing infringement of its brand-name drug’s patented uses in violation of 35 U. S. C. §271(b), so its complaint cannot withstand Hikma’s motion to dismiss.

The Court’s statement of the holding, from the opinion’s syllabus. The syllabus is prepared by the Reporter of Decisions and is not part of the opinion of the Court — read the official opinion for authority.

Read the official opinion (PDF, supremecourt.gov) (opens primary source in a new tab)

Ketanji Brown Jackson’s profile · All opinions since October Term 2017 · The Supreme Court

Source: Supreme Court of the United States, slip opinions (2026). Data last verified 2026-07-02. Informational only; verify against the primary source before relying. Not a consumer report (FCRA).